Q3 2025 Karyopharm Therapeutics Inc Earnings Call Transcript

Nov 3, 2025 / 01:00 PM GMT

Release Date Price: $6.07 (+4.66%)

Transcript 10-Q8-K

Key Points

Positve

Karyopharm Therapeutics Inc (KPTI) completed enrollment in their phase 3 Century trial for frontline myelofibrosis, marking a pivotal moment for the company.
The company secured approximately $100 million in financial flexibility through refinancing and capital restructuring, extending their cash runway into the second quarter of 2026.
Total revenue for the third quarter of 2025 was $44 million, an increase of 13% year over year, with US net product revenue growing 8.5% to $32 million.
Karyopharm's commercial organization executed well in the competitive multiple myeloma market, with Expovio net product revenue growing 8.5% year over year.
The company has a strong commercial foundation and is well-prepared for a potential transformative launch in myelofibrosis, with a peak revenue opportunity of up to approximately $1 billion annually in the US.

Negative

Karyopharm Therapeutics Inc (KPTI) reported a net loss of $33.1 million for the third quarter of 2025.
The company faces competition in the multiple myeloma market, which is highly competitive with overlapping competitors across classes.
There is uncertainty regarding the outcomes of the phase 3 Century trial, with top-line results expected in March 2026.
The company has not yet secured a partner for the Japanese market, which remains a gap in their global distribution strategy.
Interest expense remains high at $11 million for the third quarter of 2025, impacting overall financial performance.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

KPTI.OQ - Karyopharm Therapeutics Inc
Q3 2025 Karyopharm Therapeutics Inc Earnings Call
Nov 03, 2025 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning. My name is Ludy, and I will be your conference operator today.

At this time, I would like to welcome everyone to the Carrier Farm Therapeutics 3rd quarter 2025 financial results conference call. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Brandon Strong, Senior Vice President, Investor Relations and corporate communications. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good morning and thank you

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.